Adjuvants for peptide-based cancer vaccines
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possi...
Saved in:
Main Authors: | Willem W Overwijk, Hiep Khong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2016-09-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/4/1/56.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vaccine adjuvants for immunotherapy: type, mechanisms and clinical applications
by: Nimeet Desai, et al.
Published: (2025-02-01) -
Post-chemoradiotherapy adjuvant chemotherapy of rectal cancer
by: E. V. Ledin, et al.
Published: (2018-08-01) -
Adjuvanted subunit intranasal vaccine reduces SARS-CoV-2 onward transmission in hamsters
by: Yongjun Sui, et al.
Published: (2025-02-01) -
Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens
by: Chloé O. Sebilleau, et al.
Published: (2024-04-01) -
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
by: Youmei Xiao, et al.
Published: (2025-02-01)